MIDMICHIGAN MEDICAL CTR
- Type
- Teaching hospital
- Where
- MIDLAND, MI
- Medicare CCN
- 230222
- Received
- $244,600 in 97 records, 2019 ($29,603 general, $214,996 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 15 | $29,603 |
| 2019 | Research payment | 82 | $214,996 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| CSL Behring | 22 | $91,298 | 2019 |
| Abbott Laboratories | 24 | $59,550 | 2019 |
| Amgen Inc. | 9 | $21,046 | 2019 |
| Medtronic MiniMed, Inc. | 4 | $19,812 | 2019 |
| ARRAY BIOPHARMA INC | 7 | $15,354 | 2019 |
| Novartis Pharmaceuticals Corporation | 2 | $9,252 | 2019 |
| Rigel Pharmaceuticals, Inc. | 4 | $8,500 | 2019 |
| Merck Sharp & Dohme LLC | 7 | $6,391 | 2019 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $5,904 | 2019 |
| Daiichi Sankyo Inc. | 8 | $4,104 | 2019 |
| AstraZeneca Pharmaceuticals LP | 2 | $1,400 | 2019 |
| Zimmer Biomet Holdings, Inc. | 1 | $577 | 2019 |
| Edwards Lifesciences Corporation | 1 | $500 | 2019 |
| Bard Peripheral Vascular, Inc. | 1 | $500 | 2019 |
| SPS Medical Supply Corp. | 1 | $175 | 2019 |
| Siemens Medical Solutions USA, Inc. | 1 | $136 | 2019 |
| Masimo Corporation | 1 | $97 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 82 | $214,996 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $19,812 |
| Gift | 3 | $6,481 |
| Space rental or facility fees (teaching hospital only) | 5 | $2,900 |
| Education | 2 | $272 |
| Charitable Contribution | 1 | $136 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $577 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $136 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | Masimo Corporation | $97 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-21 | Amgen Inc. | $1,716 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-12-19 | Abbott Laboratories | $6,000 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-17 | ARRAY BIOPHARMA INC | $5,604 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-12-16 | Medtronic MiniMed, Inc. | $6,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-12-12 | CSL Behring | $5,400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-10 | CSL Behring | $275 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-05 | CSL Behring | $4,551 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-03 | Abbott Laboratories | $200 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-11-07 | Abbott Laboratories | $1,298 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2019 |
| 2019-11-05 | CSL Behring | $750 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-05 | CSL Behring | $475 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-30 | Abbott Laboratories | $2,138 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-10-21 | Abbott Laboratories | $4,825 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-10-21 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-10-21 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-10-17 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-17 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-10 | CSL Behring | $190 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-30 | Abbott Laboratories | $115 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-09-30 | Abbott Laboratories | $115 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-09-19 | CSL Behring | $600 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-18 | Medtronic MiniMed, Inc. | $5,343 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-09-17 | CSL Behring | $9,542 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-17 | CSL Behring | $750 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-17 | Daiichi Sankyo Inc. | $475 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-09-17 | Daiichi Sankyo Inc. | $475 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-09-05 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-08-24 | Amgen Inc. | $8,427 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-08-19 | Amgen Inc. | $363 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-08-19 | SPS Medical Supply Corp. | $175 | Education | In-kind items and services | 2019 | ||
| 2019-08-15 | AstraZeneca Pharmaceuticals LP | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-08-13 | CSL Behring | $5,681 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-08 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2019 |
| 2019-08-08 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2019 |
| 2019-08-08 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2019 |
| 2019-08-08 | Amgen Inc. | $90 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-07-31 | Abbott Laboratories | $3,063 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-07-31 | AstraZeneca Pharmaceuticals LP | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2019 | |
| 2019-07-18 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-07-11 | CSL Behring | $15,922 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-10 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-07-02 | Abbott Laboratories | $4,450 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-07-02 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-06-30 | Abbott Laboratories | $45 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-06-25 | Medtronic MiniMed, Inc. | $3,893 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-06-11 | CSL Behring | $12,195 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-30 | Daiichi Sankyo Inc. | $750 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-05-30 | Daiichi Sankyo Inc. | $500 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-05-26 | C. R. Bard, Inc. & Subsidiaries | $2,952 | Gift | In-kind items and services | ARCTIC SUN Device, MEDICAL SYSTEMS | 2019 | |
| 2019-05-26 | C. R. Bard, Inc. & Subsidiaries | $2,952 | Gift | In-kind items and services | ARCTIC SUN Device, MEDICAL SYSTEMS | 2019 | |
| 2019-05-21 | ARRAY BIOPHARMA INC | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-05-15 | Abbott Laboratories | $4,415 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-05-09 | CSL Behring | $3,537 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-04-16 | CSL Behring | $2,056 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-04-09 | CSL Behring | $9,479 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-04-01 | Abbott Laboratories | $4,450 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-04-01 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-03-29 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-03-28 | Medtronic MiniMed, Inc. | $4,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 630G Device, Durable Pump | 2019 | |
| 2019-03-27 | Amgen Inc. | $1,219 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-03-27 | Daiichi Sankyo Inc. | $599 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-03-27 | Daiichi Sankyo Inc. | $475 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-03-27 | Daiichi Sankyo Inc. | $80 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-03-26 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-03-19 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-03-14 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-08 | Merck Sharp & Dohme LLC | $3,300 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-03-07 | CSL Behring | $1,768 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-02-28 | Novartis Pharmaceuticals Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-02-26 | Amgen Inc. | $6,324 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-02-23 | Amgen Inc. | $1,000 | Research payment | Cash or cash equivalent | Kyprolis Biological, Oncology | Modified Kd56 Regimen in US Community Centers | 2019 |
| 2019-02-21 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-02-21 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-02-13 | Rigel Pharmaceuticals, Inc. | $5,000 | Research payment | Cash or cash equivalent | AIHA | C-935788-053 | 2019 |
| 2019-02-13 | Rigel Pharmaceuticals, Inc. | $2,250 | Research payment | Cash or cash equivalent | AIHA | C-935788-053 | 2019 |
| 2019-02-13 | Rigel Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | AIHA | C-935788-053 | 2019 |
| 2019-02-13 | Rigel Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | AIHA | C-935788-053 | 2019 |
| 2019-02-12 | Novartis Pharmaceuticals Corporation | $8,752 | Research payment | Cash or cash equivalent | ILARIS Biological, IMMUNOLOGY | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION | 2019 |
| 2019-02-12 | CSL Behring | $1,464 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-02-08 | Bard Peripheral Vascular, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LUTONIX Device, PERIPHERAL VASCULAR | 2019 | |
| 2019-02-06 | Abbott Laboratories | $5,834 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-02-05 | CSL Behring | $2,962 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-01-30 | Abbott Laboratories | $9,200 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-01-30 | Edwards Lifesciences Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2019 | |
| 2019-01-29 | CSL Behring | $400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-01-24 | Daiichi Sankyo Inc. | $750 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-01-23 | Amgen Inc. | $1,829 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-01-08 | CSL Behring | $11,044 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-01-03 | ARRAY BIOPHARMA INC | $5,000 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-01-03 | ARRAY BIOPHARMA INC | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-01-03 | ARRAY BIOPHARMA INC | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-01-03 | ARRAY BIOPHARMA INC | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-01-03 | ARRAY BIOPHARMA INC | $250 | Research payment | Cash or cash equivalent | A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilat | 2019 | |
| 2019-01-01 | Amgen Inc. | $77 | Research payment | In-kind items and services | GALACTIC-HF | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Midland, MI, county Midland County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Midland, MI | County Midland County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 42,724 | 83,757 | 10,077,761 |
| Population, 2020 census P1 | 42,547 | 83,494 | 10,077,331 |
| Median age B01002 | 39.3 | 41.8 | 40.2 |
| Under 18 B01001 | 21.2% | 20.9% | 21.2% |
| 65 and over B01001 | 20.4% | 20.2% | 18.6% |
| Households B11001 | 18,535 | 34,993 | 4,076,369 |
| Foreign born B05002 | 4.8% | 3.2% | 7.2% |
| Median household income B19013 | $73,325 | $77,705 | $72,875 |
| Median family income B19113 | $103,505 | $100,943 | $93,357 |
| Per capita income B19301 | $44,053 | $43,622 | $40,735 |
| Poverty rate B17001 | 10.3% | 10.7% | 13.2% |
| Unemployment rate B23025 | 4.1% | 4.4% | 5.7% |
| Civilian labor force B23025 | 20,510 | 40,590 | 5,018,449 |
| Mean commute (minutes) B08013 | 20.0 | 23.7 | 24.2 |
| Bachelor's degree or higher B15003 | 44.6% | 36.6% | 32.4% |
| Housing units B25001 | 19,459 | 37,160 | 4,622,236 |
| Owner-occupied B25003 | 67.1% | 78.1% | 73.2% |
| Renters B25003 | 32.9% | 21.9% | 26.8% |
| Median home value B25077 | $203,900 | $195,400 | $231,600 |
| Median gross rent B25064 | $1,048 | $1,016 | $1,129 |
| White, not Hispanic B03002 | 86.3% | 89.2% | 72.4% |
| Black B03002 | 2.0% | 1.2% | 13.1% |
| Hispanic or Latino B03002 | 4.6% | 3.4% | 5.9% |
| Asian B03002 | 3.3% | 2.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Midland, MI.
Comments